Control
Recent:Gaughan.
Jan 15 2023 |
et al., American Journal of Respiratory and Critical Care Medicine, doi:10.1164/rccm.202203-0477OC | An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE) |
| 40% higher mortality (p=0.7) and 100% longer hospitalization. RCT 41 hospitalized COVID-19 pneumonitis patients showing inhaled GB0139, a galectin-3 inhibitor, was well-tolerated with no treatment-related serious adverse events. There were greater rates of decline in inflammatory markers (CRP, LDH,.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.